Publications by authors named "Mark Wickens"

Claim this Profile
P
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
Stan B Kaye, Jan Lubinski, Ursula Matulonis, Joo Ern Ang, Charlie Gourley, Mark Wickens

J Clin Oncol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Andrew Tutt, Mark Robson, Judy E Garber, Susan M Domchek, M William Audeh, Mark Wickens

Lancet· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
M William Audeh, James Carmichael, Richard T Penson, Michael Friedlander, Bethan Powell, Mark Wickens

Lancet· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.
Robert F Storey, S Melissa Thornton, Rachael Lawrance, Steen Husted, Mark Wickens

Platelets· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Robert F Storey, Steen Husted, Robert A Harrington, Stanley Heptinstall, Robert G Wilcox, Mark Wickens

J Am Coll Cardiol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies.
C Michael Hill, Steen Sindet-Pederson, Robin A Seymour, John E Hawkesford, Paul Coulthard, Mark Wickens

Clin Ther· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
Steen Husted, Håkan Emanuelsson, Stan Heptinstall, Per Morten Sandset, Mark Wickens

Eur Heart J· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis